Publication Name	World Journal of Gastroenterology
Manuscript ID	124660
DOI	10.3748/wjg.124660
Country	China

Category	Oncology
Manuscript Type	Retrospective Cohort Study
Article Title	Programmed cell death protein 1 inhibitor combination therapy as first-line treatment for unresectable or metastatic combined hepatocellular-cholangiocarcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Yang Tan, Zi-Yue Huang, Shan-Shan Wang, Yu Wu, Zi-Bo Xu, Bo-Yu Sun, Jing Zhang, Xiao-Bo Yang, Cheng-Pei Zhu, Dao-Bing Zeng and Hai-Tao Zhao
Funding Agency and Grant Number	Funding Agency Grant Number Beijing Natural Science Foundation L248022 National High Level Hospital Clinical Research Funding 2025-PUMCH-C-015 National High Level Hospital Clinical Research Funding 2025-PUMCH-D-001
Corresponding Author	Hai-Tao Zhao, MD, Professor, Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 1 Shuaifuyuan, Dongcheng District, Beijing, Beijing 100730, China. zhaoht@pumch.cn
Key Words	Combined hepatocellular-cholangiocarcinoma; Immunotherapy; Programmed cell death protein 1 inhibitors; First-line treatment; Combination therapy; Biomarkers
Core Tip	There remains limited evidence to guide the optimal first-line systemic therapy for unresectable or metastatic combined hepatocellular-cholangiocarcinoma (cHCC-CCA), a rare and aggressive liver cancer. This multicenter retrospective cohort study evaluated the efficacy and safety of programmed cell death protein 1 inhibitor-based combination therapy in 31 patients with unresectable or metastatic cHCC-CCA. The regimen demonstrated a median overall survival of 15.8 months and a manageable safety profile. Furthermore, elevated baseline levels of serum carcinoembryonic antigen and carbohydrate antigen 19-9 may serve as independent prognostic biomarkers for survival. This evidence supports the potential role of this combination as a treatment option for this challenging disease.
Citation	Tan Y, Huang ZY, Wang SS, Wu Y, Xu ZB, Sun BY, Zhang J, Yang XB, Zhu CP, Zeng DB, Zhao HT. Programmed cell death protein 1 inhibitor combination therapy as first-line treatment for unresectable or metastatic combined hepatocellular-cholangiocarcinoma. World J Gastroenterol 2026; In press DOI: https://doi.org/10.3748/wjg.124660
PDF	124660-in-press.pdf

Received	2026-06-22 07:04
Peer-Review Started	2026-06-22 07:05
First Decision by Editorial Office Director
Return for Revision	2026-07-10 02:59
Revised	2026-07-24 03:05
Publication Fee Transferred	2026-08-20 08:34
Second Decision by Editor	2026-09-24 02:42
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-09-24 08:48
Articles in Press	2026-09-24 08:48
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com